WO2006038550A1 - 原虫寄生感染症の予防又は治療用医薬組成物 - Google Patents
原虫寄生感染症の予防又は治療用医薬組成物 Download PDFInfo
- Publication number
- WO2006038550A1 WO2006038550A1 PCT/JP2005/018093 JP2005018093W WO2006038550A1 WO 2006038550 A1 WO2006038550 A1 WO 2006038550A1 JP 2005018093 W JP2005018093 W JP 2005018093W WO 2006038550 A1 WO2006038550 A1 WO 2006038550A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- membered
- general formula
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/84—Naphthothiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- composition for prevention or treatment of protozoan parasitic infection comprising
- the present invention relates to a pharmaceutical composition useful for the prevention or treatment of parasitic protozoal infections.
- Parasitic protozoal infections are still widely known, particularly in the tropical and subtropical regions, such as malaria, leishmaniasis, African 'trypanosomatosis (African sleep disease), the United States ⁇ There are trypanosomiasis (shear gas disease), lymphofilariasis, babesiosis. These are classified as those that infect only humans or those that are zoonotic infecting livestock and small animals, both of which cause significant economic and social damage. Among these diseases, there are some drugs that are not fully effective, and the emergence and spread of resistant protozoa to the drugs, as well as side effects of the drugs, are effective. Drugs are anxious.
- pentostam which is a Leishmania therapeutic agent currently used, has an antimony atom in its molecule, so antimony poisoning is inevitable as a side effect of treatment.
- Meralsoprol which is used for the initial treatment of African trypanosooma (African sleeping sickness), contains an arsenic atom in the molecule, and arsenic poisoning occurs as a side effect.
- the compound represented by the general formula (1) contained in the pharmaceutical composition of the present invention is known as an antitumor agent having high selectivity for cancer cells (for example, Europe No. 52,494, JP-A-5-117148, and US Pat. No. 5,861,424)), and its use as a preventive or therapeutic agent for parasitic protozoal infections is not known .
- the present inventors have clarified that the rhodayanine compound represented by the following general formula (3) has a therapeutic effect on malaria and leishmaniasis (see, for example, JP-A-2000-1).
- R 7 and R 9 each independently represents an alkyl group
- R 8 represents an alkyl group, an aryl group, or a heterocyclic group
- C and D are Each independently represents a group of atoms required to form a 5- or 6-membered complex ring
- P represents a physiologically acceptable anion
- a represents zero charge across the molecule. Represents an integer of 0 to 2 necessary for this, and b represents 0 or 1.
- Patent Document 1 European Patent No. 527,494
- Patent Document 2 JP-A-5-117148
- Patent Document 3 US Pat. No. 5,861,424
- Patent Document 4 Japanese Unexamined Patent Publication No. 2000-191531.
- Patent Document 5 Special Translation 2003—No. 034640
- Patent Document 6 Japanese Unexamined Patent Application Publication No. 2003-034641
- Patent Document 7 Japanese Unexamined Patent Publication No. 2003-034642
- the object of the present invention is to have high selective toxicity against parasitic protozoal infections
- Corrected form (Rule 91) It is to provide a pharmaceutical composition for the prevention or treatment of protozoan parasitic infections having a prophylactic or therapeutic effect.
- the inventors of the present invention have tested the proliferative effect of protozoa causing disease on a wide variety of compounds that can solve the above-mentioned problems, and further have cytotoxicity against mammalian cells that serve as an indicator of side effects. As a result of repeated studies such as evaluation, the present inventors have found that the compound represented by the general formula (1) of the present invention is very effective against parasitic protozoal infections, thereby completing the present invention. It was.
- a pharmaceutical composition for preventing or treating protozoan parasitic infection comprising a compound represented by the following general formula (1) as an active ingredient:
- R represents an alkyl group, an aryl group or a heterocyclic group
- a and B each independently represent a 5-membered or 6-membered ring containing at least one heteroatom, or 1 or 2 or more condensed 3- to 8-membered rings are condensed
- Y is S, 0, Se, or —NR 1 — (R 1 is an alkyl group, aryl group, or heterocycle.
- L 1 , L 2 , L 3 , L 4 and L 5 each independently represents a methine group
- Q represents a physiologically acceptable ion
- k Indicates an integer from 0 to 2 that is necessary to make the charge of the whole molecule zero
- p and q are integers in which the sum of p and q is 1 or more and 6 or less in the range of 0 to 3, respectively.
- [2] 1 ⁇ and Z or L 5 are substituted methine groups, and the atoms constituting L 1 and A and the atoms constituting Z or L 5 and B are bonded together to form 5 or [1] characterized by forming a 6-membered ring
- the pharmaceutical composition for prevention or treatment of protozoan parasite infection described in [3] —a compound represented by the general formula (1) is a compound represented by the following general formula (2):
- R 2 and R 3 each independently represents an alkyl group
- one CR 4 R 5 — (R 4 and R 5 each independently represents an alkyl group), or NR 6 — (R 6 represents an alkyl group, an aryl group, or a heterocyclic group)
- Z 1 and Z 2 each independently represent a 5-membered ring or a 6-membered ring, or an atomic group necessary to form a condensed ring in which 1 or 2 or more 3- to 8-membered rings are condensed
- m and n are each 0 or 1.
- ML 1 and Z or L 5 are substituted methine groups, and L 1 and R 2 and Z or L 5 and R 3 are bonded to form a 5- or 6-membered ring.
- the pharmaceutical composition for prevention or treatment of protozoan parasitic infection as described in [3] above, or [5] Q is a halogen ion, sulfonate ion, or carboxylate ion [1] to [4] for the prevention or treatment of protozoan parasitic infections, and [6] protozoan parasitic infections are malaria, leishmaniasis, African 'trypanosomatosis Or a pharmaceutical composition for the prevention or treatment of protozoan parasitic infection according to any one of [1] to [5] above, characterized in that it is American 'trypanosomatosis.
- the pharmaceutical composition for preventing or treating protozoan parasitic infections of the present invention (hereinafter simply referred to as the pharmaceutical composition of the present invention) comprises a compound represented by the following general formula (1) as an active ingredient.
- the compound represented by the general formula (1) is not particularly limited as long as it is a contained pharmaceutical composition, and may be contained in one kind or two or more kinds. In combination with an acceptable carrier or diluent.
- R represents an alkyl group, an aryl group or a heterocyclic group.
- alkyl group represented by R in the general formula (1) those having 1 to 15 carbon atoms are preferable, and those having 1 to 7 are more preferable. It may be annular.
- the preferred alkyl group which may be substituted is preferably an alkyl group having 1 to 15 carbon atoms, an alkyl group having 2 to 15 carbon atoms, an alkyl group having 2 to 15 carbon atoms, An alkoxy group having 1 to 15 carbon atoms, an aryloxy group having 6 to 15 carbon atoms, a halogen atom (chlorine, bromine, fluorine, iodine, etc.), an aryl group having 6 to 15 carbon atoms, a hydroxyl group, an amino group, an alkyl group, or An amino group substituted by an aryl group, an acylamino group, a sulfo-lumino group, a strong rubamoyl group, a sulfamoyl group, a carboxyl group, an alkoxycarbo group having 2 to 15 carbon atoms, an acyloxy group having 2 to 15 carbon atoms, Examples thereof include a 5-membered or 6-membered hetero
- alkyl group represented by R examples include a methyl group, an ethyl group, a hydroxyethyl group, a 2-propyl group, a benzyl group, a propyl group, and a butyl group.
- aryl group represented by R in the general formula (1) those having 5 to 15 carbon atoms are preferable, and those having 6 to 10 carbon atoms are more preferable.
- substituent which may be substituted in the strong aryl group include those similar to those in the above alkyl group.
- Specific aryl groups represented by R include a phenyl group, a tolyl group, a p-chlorophenol group, a 1-naphthyl group, a 2-naphthyl group, and the like.
- the heterocyclic group represented by R in the general formula (1) may be a saturated ring or an unsaturated ring, and a 5- to 8-membered ring is preferred. A ring is more preferred.
- the hetero atom include a nitrogen atom, an oxygen atom, a sulfur atom, a selenium atom, a tellurium atom, and a phosphorus atom, and a nitrogen atom, an oxygen atom, a sulfur atom, and a selenium atom are preferable.
- Powerful heterocyclic group is substituted Examples of the substituent that may be used include the same substituents as those described above for the alkyl group.
- heterocyclic group represented by R examples include a pyrrole group, a furan group, a piperidine group, a morpholine group, a piperazine group, a pyridine group, and a pyrrolidine group.
- a and B are each independently a 5-membered ring or 6-membered ring containing at least one heteroatom, or 1 or 2 or more 3- to 8-membered rings. Represents a fused condensed ring.
- the 5-membered or 6-membered ring containing at least one heteroatom represented by A and B in the general formula (1) can be either a saturated ring or an unsaturated ring.
- Examples of the hetero atom contained in the 5-membered ring or 6-membered ring include a nitrogen atom, an oxygen atom, a sulfur atom, a selenium atom, a tellurium atom, a silicon atom, and a phosphorus atom. It is preferable to include.
- the 3- to 8-membered ring in the condensed ring represented by A and B in which one or two or more 3- to 8-membered rings are condensed to the 5-membered or 6-membered ring is a saturated ring.
- cyclopropane ring for example, cyclopropane ring, cyclopropene ring, cyclobutane ring, cyclobutene ring, cyclopentane ring, cyclopentene ring, cyclohexane ring, cyclohexene ring, cycloheptane ring, cycloheptene ring , Cyclooctane ring, cyclooctene ring, benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, thiophene ring, pyridine ring, and the like.
- a and B may have 1 or 2 or more substituents.
- the same substituents as those for the alkyl group represented by R in the general formula (1) may be used. Can be mentioned.
- Y represents S, 0, Se, or one NR 1, and among these, S or 0 is preferable.
- R 1 represents an alkyl group, an aryl group or a heterocyclic group, and has the same meaning as the alkyl group, aryl group or heterocyclic group represented by R in the general formula (1).
- L 1 , L 2 , L 3 , L 4 and L 5 each independently represent a methine group and may have a substituent.
- a substituent an alkyl group having 1 to 15 carbon atoms (eg, methyl, ethyl, propyl, butyl group, etc.), an aryl group having 6 to 15 carbon atoms (eg, phenyl, tolyl, naphthyl group, etc.), A halogen atom (chlorine, bromine, fluorine and iodine), an alkenyl group having 2 to 15 carbon atoms (eg, an etulyl group, a 1-propenyl group), an alkynyl group having 2 to 15 carbon atoms (eg, an ethynyl group), Examples thereof include an alkoxy group having 1 to 15 carbon atoms (for example, methoxy, ethoxy group, etc.).
- L 1 is a substituted methine group
- L 5 is a substituted methine group
- the atoms constituting L 5 and B The five-membered or six-membered ring that can form a five-membered or six-membered ring includes five-membered heterocycles (for example, pyrroline ring) and six-membered heterocycles (for example, tetrahydro Pyrrolidine ring, oxazine ring, etc.).
- Q represents a physiologically acceptable ion.
- a strong physiologically acceptable anion is nontoxic when a compound represented by the general formula (1) is administered to a recipient, and the compound represented by the general formula (1) is an aqueous system.
- Means ions dissolved in Physiologically acceptable ions represented by Q include, for example, halogen ions such as chloride ion, bromide ion and iodine ion; methanesulfonate ion, trifluoromethanone phosphonate, p-tonoreens nore.
- Sulfonate ions such as aliphatic and aromatic sulfonate ions such as phosphonate, naphthalene sulfonate and 2-hydroxyethane sulfonate; sulfamate such as cyclohexane sulfamate; Sulfate ions such as til sulfate ion and ethyl sulfate ion; hydrogen sulfate ion; borate ion; alkyl and dialkyl phosphate ions such as jetyl phosphate ion and methyl hydrogen phosphate ion; pyrophosphate ion such as trimethyl pyrophosphate ion; Acid ion (carboxy group and hydroxyl group Substituted carboxylate ions are conveniently used); carbonate ions; bicarbonate ions and hydroxide ions; acetate ions; propionate ions; valeric acid ions; citrate ions; maleate
- k represents an integer of 0 to 2 required to make the charge of the whole molecule zero
- p and q are the sum of p and q in the range of 0 to 3, respectively.
- the compound represented by the general formula (1) is preferably a compound represented by the following general formula (2).
- R 2 and R 3 each independently represent an alkyl group, and have the same meaning as the alkyl group represented by ie in the general formula (1).
- L 1 and R 2 may be bonded to form a 5- or 6-membered ring.
- L 5 is a substituted methine group
- L 5 and R 3 may be bonded to form a 5- or 6-membered ring.
- the ring formed by the bond between L 1 and R 2 , L 5 and R 3 is preferably a 5-membered heterocycle (for example, a pyrroline ring) and a 6-membered heterocycle (for example, a tetrahydropyrrolidine ring). And oxazine ring).
- the alkyl group represented by R 4 to R 6 and the aryl group heterocycle group represented by R 6 have the same meaning as those represented by R in the general formula (1).
- Z 1 and Z 2 each independently form a 5-membered ring or a 6-membered ring, or a condensed ring in which 1 or 2 or more 3- to 8-membered rings are condensed to this.
- the 5-membered or 6-membered ring formed by the atomic group represented by Z 1 and Z 2 is N, X 1 , Z 1 or N +, X 2 , Z of the compound represented by the general formula (2) It refers to a ring formed by respective annular portions including 2 as the Z 1 and Z 2, specifically, methylene group, an ethylene group, a vinylene group and the like.
- hetero rings that are 5-membered or 6-membered rings formed by the atomic group represented by Z 1 and Z 2 include thiazole-based rings (for example, thiazole, 4-methylthiazole, 4 Phenylthiazole, 4,5-diphenylthiazole, 4,5-dimethylthiazole, etc., benzothiazole ring (eg, benzothiazole, 5-methylbenzothiazole, 5-phenylbenzothiazole, 5-methoxybenzothiazole , 4 Fluorobenzothiazole, 5, 6-Dioxymethylenebenzothiazole, 5-Nitrobenzothiazole, 5 Trifluoromethylbenzothiazole, 5-Methoxycarbonylbenzothiazole, 6 -Hydroxybenzothiazole, 5-cyanobenzothiazole, 5-oodobenzothiazol, etc.), naphthothiazole ring (eg, a naphthothiazole, ⁇ -n
- Z 1 and Z 2 may be a condensed ring in which one or two or more, 3- to 8-membered rings, preferably 5- or 6-membered rings are condensed to the 5-membered or 6-membered ring.
- 1 or 2 or more 3- to 8-membered rings may be saturated or unsaturated, for example, cyclopropan ring, cyclopropene ring, cyclobutane ring, cyclobutene ring, cyclopentane Ring, cyclopentene ring, cyclohexane ring, cyclohexene ring, cycloheptane ring, cycloheptene ring, cyclooctane ring, cyclootaten ring, benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, thiophene ring, pyridine ring, etc. Is mentioned.
- the 5-membered ring, 6-membered ring and condensed ring may have 1 or 2 or more substituents, and the substituents which may be included are those of the alkyl group represented by R in the general formula (1). The same thing as a substituent is mentioned.
- n each represents 0 or 1.
- Typical examples of the compounds represented by the general formulas (1) and (2) of the present invention include the following. The following compounds are not limited to these compounds.
- the pharmaceutical composition of the present invention comprises malarial disease, leishmaniasis, African 'trypanosomiasis (African sleep disease), American' trypanosomiasis (shear gas disease), lymphatic filariasis, babesiosis, and other parasitic diseases. Prevention or prevention of various types of diseases caused by infection with protozoa Can be used effectively for treatment.
- the pharmaceutical composition of the present invention can contain an anti-protozoan infection agent, if necessary, using conventional force.
- Preferred examples of such conventionally used antiprotozoal agents include black mouth kin, mefloquine, artemisinin, atobacon, pyrimesamine (above, drugs for treating malaria); suramin, pentamidine (above, Africa)
- Therapeutic agents for trypanosomiasis include benznidazole, primaquine (above America's trypanosomiasis), pentostam, amphotericin B, mirteforn (below, leishmaniasis).
- a pharmaceutical carrier or diluent that can be used together with the compounds represented by the general formula (1) and general formula (2) of the present invention
- a pharmaceutical carrier or diluent that has been conventionally used is used.
- glucose for example, glucose; saccharose; latose; ethylanoloreconole; glycerin; mannitol; sorbitol; pentaerythritol; diethyleneglycolene, propylene glycol, dipropylene glycol, polyethylene glycol 400, multiple polyethylene glycols; glyceryl trilaurate, and distearic acid
- Fatty acids such as glyceryl and triglycerides
- Pectin Starch; Arginic acid; Xylose; Talc; Ishimatsuko; Olive oil, Peanut oil, Castor oil, Corn oil, Safflower oil, Wheat malt oil, Sesame oil, Fruit And oils and fats such as sunflower oil and cod liver oil; gelatin
- Esters with monohydric aliphatic or polyhydric alcohols having 1 to 20 carbon atoms such as ethyl alcohol, butyl alcohol, octadecyl alcohol; Examples thereof include silicone such as til polysiloxane.
- the pharmaceutically effective amount and the administration method or administration means of the compounds represented by the general formula (1) and the general formula (2) of the present invention are the kinds of parasitic protozoa that cause infection, Dependent on protozoan parasite, severity of disease, treatment strategy, patient age, weight, gender, general health, and patient's (genetic) racial background.
- the dose of the present invention is 1 to 2000 mg, more generally 50 to 500 mg Z day 70 kg body weight, and a preferable administration method is, for example, a solution in 5% glucose aqueous solution.
- Examples of the method include intravenous injection, intraperitoneal injection, subcutaneous injection, oral capsule application, or application to the skin in the form of the above or with the carrier or diluent.
- Plasmodium Falciparum FCR-3 strain protozoa was used.
- the medium used in the experiment was RPMI-1640 medium sterilized by filtration, adjusted to pH 7.4, and human serum was added to 10%.
- the malaria parasite culture is 5% O concentration, 5% CO concentration, N concentration 90
- plasmodium-infected erythrocytes were collected by centrifugation, washed with serum-containing medium, and non-infected erythrocytes were added to give an initial infection rate of 0.3%. The hematocrit value at this time was 3%.
- the compounds of the present invention and positive target drugs (Kuroguchikin, quinine) used in the test were dissolved in dimethyl sulfoxide (DMSO) to obtain a test solution having a predetermined concentration. 5 to 10 ⁇ L of the test solution was added to each 24-well culture plate.
- the control was DMSO 10 ⁇ LZ uelcaro.
- the test solution was duplicated.
- a Plasmodium falciparum culture solution prepared in advance at a predetermined concentration was added, and gently suspended by pipetting and suspended uniformly in the medium. Culture plate is 72 hours in CO -0 -N (5%, 5%, 90%) incubator
- the malaria parasite infection rate calculated above The growth inhibition rate was calculated by the following formula, and the 50% growth inhibitory concentration (EC) was obtained.
- F28-7 strain a wild strain of mouse breast cancer-derived FM3A cells, was used.
- the culture medium was added to ES medium with non-immobilized fetal bovine serum at 2% and cultured at a CO concentration of 5% at 37 ° C.
- the doubling time of FM3A cells was about 12 hours.
- Pre-culture was performed, and cells in the logarithmic growth phase were diluted with a medium so as to be 5 ⁇ 10 4 cells / mL.
- the sample used was prepared at the time of measuring malaria activity.
- the sample solution was added to a 24-well culture plate in 5 to LO / zL increments (the final concentration became 1 x 10 4 to 1 x 10 _5 M when the medium was added).
- the compound was duplicated and a well with 10 L DMSO added as a control.
- the prepared cultured cell suspension was added 990-995 at a time, and gently pipetted to suspend uniformly in the medium. After culturing for 48 hours, the number of cells for each well was counted with a cell controller (CC-108, manufactured by Toa. Medical Electronics), the growth rate was calculated by the following formula, and the 50% growth inhibition rate (EC) was calculated.
- the cell growth inhibitory activity was calculated by calculating the number of cells in the well to which the sample was added and the number of cells in the control. This evaluated the cytotoxicity of the sample.
- EC50 values of samples for drug-sensitive P. falciparum and mouse FM3A cells The antimalarial activity of the force samples was evaluated.
- the chemotherapeutic coefficient used as an index of selective toxicity to drug-sensitive malaria parasites was calculated by the following formula to determine the efficacy.
- Table 1 shows each EC value of the sample against the drug-sensitive P. falciparum and mouse FM3A cells and the selective toxicity coefficient for the compound of the present invention and the positive target drug.
- the compound of the present invention showed a growth inhibitory effect equivalent to or higher than that of the existing drugs quinine and black mouth quinn. In addition, it was not able to show strong toxicity to normal cells.
- Example 2
- Plasmodium Falciparum K1 protozoa was used.
- the medium used in the experiment was RPMI-1640 medium sterilized by filtration, and human serum was added to 5%. Plasmodium was cultured at 3% O, 4% CO, 93% N, and a temperature of 37 ° C.
- the compound of the present invention and the positive target drug (Kuroguchikin) used in the test were dissolved in DMSO to prepare a test solution having a predetermined concentration.
- Cultured plasmodium-infected erythrocytes are collected by centrifugation and non-infected Dilution with erythrocytes gave an initial infection rate of 0.15%. The hematocrit value at this time was 2.5%.
- 200 L of a malaria-infected culture solution was added, and a test solution containing a predetermined concentration of the drug or DMS 0 containing the drug was added for adjustment. The test solution was duplicated.
- Rat-derived L6 cells (rat skeletal myoblast cells) were used.
- the medium is RPMI 1640 medium supplemented with 1% L-glutamine (200 mM) and 10% fetal calf serum.
- the cells were cultured at a concentration of 5% and 37 ° C.
- the compound of the present invention or the target drug used for the test was dissolved in DMSO to obtain a test solution having a predetermined concentration.
- Preculture was performed, and the medium containing cells in the logarithmic growth phase was taken into a well of a 96-well culture plate, and then a test solution containing a predetermined concentration of drug or DMS O containing no drug was prepared.
- the test solution was duplicated. After culturing the culture plate in an incubator for 72 hours, the growth inhibitory activity was assayed.
- the test was performed as follows.
- chemotherapeutic coefficient used as an index of selective toxicity to black mouth quinine-resistant Plasmodium was calculated according to the following formula to determine the efficacy.
- Table 2 shows the EC values and selective toxicity coefficients of the samples of the present compound and the positive target drug for each of Kuroguchikin-sensitive P. falciparum and rat L5 cells.
- the compound of the present invention showed a growth inhibitory effect equivalent to or higher than that of the existing drug, Kuroguchikin. In addition, it did not show strong toxicity to normal cells. That is, it can be evaluated as effective as an anti-drug resistant malaria drug.
- Trypanosoma brucei rhodensiense (STIB900 strain) protozoan blood flow respiratory type tripomastigote body was used.
- the medium used in the experiment was sterilized by filtration in MEM medium, 25 mM N-2-hydroxyethylpiperazine 2 ethanethrophonic acid (HEPES), lgZL glucose, 1% MEM non-essential amino acid, 0.2 mM 2-mercapto.
- Ethanol, 2 mM sodium pyruvate flame, 0. ImM hypoxanthine and 15% heat-treated horse serum were used.
- Protozoan culture is performed in air at a CO concentration of 5%
- the compound of the present invention and the positive target drug (Meralsoprol) used in the test were dissolved in dimethyl sulfoxide (DMSO) to prepare a test solution having a predetermined concentration.
- DMSO dimethyl sulfoxide
- the test solution was taken in duplicate. After culturing the culture plate in an incubator for 72 hours, the growth inhibitory activity was assayed.
- the test was performed as follows. To each well, 10 ⁇ L of Alamar Blue aqueous solution was added and further cultured for 2 hours.
- the culture plate was mounted on a fluorescence microplate reader (Spectramax Gemeni XS; manufactured by Molecular Devices, Inc., USA), irradiated with an excitation wavelength of 536 nm, measured for fluorescence intensity at 588 nm, and the test solution addition group and The control trypanosomes protozoa infection rate was calculated.
- the protozoa infection rate calculated above
- the growth inhibition rate was calculated by the following formula, and the 50% growth inhibitory concentration (EC) was calculated.
- the selective toxicity coefficient used as an indicator of selective toxicity to African 'trypanosomyma parasites was calculated by the following formula and the efficacy was evaluated.
- Table 3 shows the EC values and selective toxicity coefficients of the samples of the compounds of the present invention and the positive target drug against all African Trypanosoma protozoa and rat L6 cells.
- the compound of the present invention showed an inhibitory effect on the growth of African trypanosomes similar to that of the existing drug meralsoprol. In addition, it showed weaker or equivalent toxicity to normal cells compared to existing drugs. That is, anti-African 'trypanoso-ma (African sleep It can be evaluated as effective as a disease) drug. Further, since these inventions do not have an arsenic atom in the molecule, they do not give serious side effects such as arsenic poisoning to patients.
- amastigotes and tripomastigotes infected with Trypanosoma cruzi (Tulahuen C2C4 strain) protozoan rat L6 cells were used.
- the medium used in the experiment was added to RPMI1640 medium containing L6 cells so that L-glutamine (200 mM) was 1% and fetal bovine serum was 10%, and the CO concentration was 5%.
- the compound of the present invention and the positive target drug (benznidazole) used in the test were dissolved in DMSO to obtain a test solution having a predetermined concentration.
- the Ueru of 96-well culture plate, the number of parasites was conducted for 48 hours preculture added medium containing 3 5Xl0. After changing the medium, DMS 0 was added without a test solution or drug containing a predetermined concentration of drug.
- the test solution was duplicated. After culturing the culture plate in an incubator for 96 hours, the growth inhibitory activity was assayed. The test was performed as follows.
- Each well was covered with 50 ⁇ L of CPRGZNonidet and allowed to stand for another 2-6 hours.
- the culture plate was attached to an absorption microplate reader, the absorbance at 540 nm was measured, and the trypanosomes protozoa infection rate of the test solution addition group and the control was calculated. The rate was calculated and the 50% growth inhibitory concentration (EC) was determined.
- the selective toxicity coefficient used as an indicator of selective toxicity to American 'trypanosomyma parasites was calculated by the following formula, and the efficacy was evaluated.
- Table 4 shows the EC values of the samples against the American 'Tripanosomes protozoa and rat L6 cells, and the selective toxicity coefficient for the compound of the present invention and the positive target drug.
- the compound of the present invention showed an inhibitory effect on the growth of protozoa of American trypanosomes equivalent to the existing drug benznidazole.
- the toxicity was strong against normal cells. In other words, it can be evaluated as an anti-American trypanosoma (shear gas disease) drug with few side effects.
- Leishmania donovani (MHOM / ET / 67 / L82 strain) was used.
- the protozoa was subcultured with Syrian Golden Nomstar, and the power was obtained.
- SM medium supplemented with 10% heat-treated rabbit fetal serum was adjusted to pH 5.4 and cultured at 37 ° C in air with a CO concentration of 5%.
- the positive target drug (miltefosine) is dissolved in DMSO, A test solution having a predetermined concentration was obtained. After pretreatment of a 96-well culture plate well containing a predetermined number of protozoa, the concentration of amastigotes was measured with a CASY cell analysis system (manufactured by Scharfe, Germany). Thereafter, a test solution containing a predetermined concentration of drug or DMS O containing no drug was prepared. The test solution was duplicated. After culturing the culture plate in an incubator for 72 hours, the growth inhibitory activity was assayed. The test was conducted as follows.
- the selective toxicity coefficient used as an indicator of selective toxicity to Leishmania parasites was calculated using the following formula to determine the efficacy.
- Table 5 shows the EC values of the samples against Leishmania protozoa and rat L6 cells and the selective toxicity coefficient for the compound of the present invention and the positive target drug.
- the compound of the present invention showed a leishmania protozoan growth inhibitory effect equivalent to that of the existing drug miltefosine. Also, the toxicity was weak against normal cells. In other words, it can be evaluated as an anti-leisure drug with few side effects.
- the compound of the present invention exhibits a growth inhibitory effect even when administered at a low dose against parasitic protozoan infections, and the dose is higher than the dose showing protozoa growth inhibition It was clarified that the administration of this does not damage mammalian cells. That is, these facts revealed that the compound of the present invention is suitable as a preventive or therapeutic agent for protozoan parasitic infections.
- a pharmaceutical composition for the prevention or treatment of protozoan parasitic infections that has high and selective toxicity against parasitic protozoal infections and has a high V epilepsy prevention or treatment effect. Can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05787692.2A EP1800682B1 (en) | 2004-10-04 | 2005-09-30 | Medicinal composition for prevention or treatment of parasitic protozoan infection |
CN2005800331728A CN101031295B (zh) | 2004-10-04 | 2005-09-30 | 原生动物感染病的预防或治疗用药物组合物 |
US11/576,429 US8193224B2 (en) | 2004-10-04 | 2005-09-30 | Medicinal composition for prevention or treatment of parasitic protozoan infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-292002 | 2004-10-04 | ||
JP2004292002A JP4553355B2 (ja) | 2004-10-04 | 2004-10-04 | トリパノソーマ原虫寄生感染症の予防又は治療用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038550A1 true WO2006038550A1 (ja) | 2006-04-13 |
Family
ID=36142625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/018093 WO2006038550A1 (ja) | 2004-10-04 | 2005-09-30 | 原虫寄生感染症の予防又は治療用医薬組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8193224B2 (ja) |
EP (1) | EP1800682B1 (ja) |
JP (1) | JP4553355B2 (ja) |
CN (1) | CN101031295B (ja) |
WO (1) | WO2006038550A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090076067A1 (en) * | 2005-06-24 | 2009-03-19 | Japan Science And Technology Agency | Pharmaceutical composition comprising azarhodacyanine compound as active ingredient |
JP4431796B2 (ja) * | 2006-10-10 | 2010-03-17 | 国立大学法人 岡山大学 | 新規な抗マラリア剤 |
WO2011046158A1 (en) * | 2009-10-13 | 2011-04-21 | Hoshi University | Rhodacyanine derivative and pharmaceutical composition for treating leishmaniasis |
JP7450945B2 (ja) | 2018-08-30 | 2024-03-18 | テナヤ セラピューティクス, インコーポレイテッド | ミオカルディンおよびascl1を用いた心細胞リプログラミング |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US692347A (en) | 1901-04-29 | 1902-02-04 | George O Redpath | Comb for spacing the mesh of woven fabrics. |
EP0527494A1 (en) | 1991-08-13 | 1993-02-17 | Fuji Photo Film Co., Ltd. | Compositon containing rhodacyanine dyes for treating cancer |
JPH05117148A (ja) | 1991-04-26 | 1993-05-14 | Fuji Photo Film Co Ltd | 抗癌性組成物 |
US5861424A (en) | 1991-04-26 | 1999-01-19 | Dana Farber Cancer Institute | Composition and method for treating cancer |
JP2000191531A (ja) | 1998-12-28 | 2000-07-11 | Fuji Photo Film Co Ltd | 抗マラリア剤 |
JP2003034642A (ja) | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン色素化合物を含有する抗マラリア剤 |
JP2003034641A (ja) | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン系色素化合物を含有する抗マラリア剤 |
JP2003034640A (ja) | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | 四環性複素化合物を含有する抗マラリア剤 |
JP2004331545A (ja) * | 2003-05-06 | 2004-11-25 | Japan Science & Technology Agency | 抗リーシュマニア剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB489335A (en) * | 1937-01-22 | 1938-07-22 | Douglas James Fry | Improvements in or relating to the manufacture and use of dyestuffs suitable for sensitising photographic emulsions |
OA03835A (fr) * | 1970-07-17 | 1971-12-24 | Rhone Poulenc Sa | Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent. |
US4443455A (en) * | 1978-02-17 | 1984-04-17 | Imperial Chemical Industries Plc | Fungidical thiazolidinones |
JP2684267B2 (ja) * | 1990-11-28 | 1997-12-03 | 富士写真フイルム株式会社 | シアン画像形成方法及びハロゲン化銀カラー写真感光材料 |
US5476945A (en) * | 1992-11-17 | 1995-12-19 | Fuji Photo Film Co., Ltd. | Water-soluble methine derivatives of thiazole |
US5618831A (en) * | 1992-11-17 | 1997-04-08 | Fuji Photo Film Co., Ltd. | Composition and method for treating cancer |
JPH06234932A (ja) * | 1993-02-09 | 1994-08-23 | Fuji Photo Film Co Ltd | メチン化合物 |
EP0772607A1 (en) | 1994-07-21 | 1997-05-14 | Fuji Photo Film Co., Ltd. | Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same |
US5599825A (en) * | 1994-07-21 | 1997-02-04 | Fuji Photo Film Co., Ltd. | Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same |
US6506751B1 (en) * | 1999-11-12 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Thiazolidinone compounds useful as chemokine inhibitors |
WO2003060078A2 (en) * | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
-
2004
- 2004-10-04 JP JP2004292002A patent/JP4553355B2/ja active Active
-
2005
- 2005-09-30 WO PCT/JP2005/018093 patent/WO2006038550A1/ja active Application Filing
- 2005-09-30 EP EP05787692.2A patent/EP1800682B1/en active Active
- 2005-09-30 CN CN2005800331728A patent/CN101031295B/zh active Active
- 2005-09-30 US US11/576,429 patent/US8193224B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US692347A (en) | 1901-04-29 | 1902-02-04 | George O Redpath | Comb for spacing the mesh of woven fabrics. |
JPH05117148A (ja) | 1991-04-26 | 1993-05-14 | Fuji Photo Film Co Ltd | 抗癌性組成物 |
US5861424A (en) | 1991-04-26 | 1999-01-19 | Dana Farber Cancer Institute | Composition and method for treating cancer |
EP0527494A1 (en) | 1991-08-13 | 1993-02-17 | Fuji Photo Film Co., Ltd. | Compositon containing rhodacyanine dyes for treating cancer |
JP2000191531A (ja) | 1998-12-28 | 2000-07-11 | Fuji Photo Film Co Ltd | 抗マラリア剤 |
JP2003034642A (ja) | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン色素化合物を含有する抗マラリア剤 |
JP2003034641A (ja) | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン系色素化合物を含有する抗マラリア剤 |
JP2003034640A (ja) | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | 四環性複素化合物を含有する抗マラリア剤 |
JP2004331545A (ja) * | 2003-05-06 | 2004-11-25 | Japan Science & Technology Agency | 抗リーシュマニア剤 |
Non-Patent Citations (7)
Title |
---|
E.B.K. NOTT ET AL., J. CHEM. SOC., 1952, pages 4762 |
KAWAKAMI ET AL., J. MED. CHEM., 1997, pages 3151 |
KAWAKAMI M ET AL: "Structure-Activity of Novel Rhodacyanine Dyes as Antitumor Agents", J. MED. CHEM., vol. 41, 1998, pages 130 - 142, XP002998989 * |
KAWAKAMI M ET AL: "Synthesis and Evaluation of Novel Rhodacyanine Dyes That Exhibit Antitumor Activity", J. MED. CHEM., vol. 40, 1997, pages 3151 - 3160, XP002998988 * |
KAZUKI KASAI: "Nettai Kansensho Chiryoyaku no Kaihatsu: Kyoekisa no Nagai Rhodacyanine no Gosei to Kassei", NIPPON YAKUGAKUKAI NENKAI KOEN YOSHISHU, 2005, pages 199, XP002998990 * |
See also references of EP1800682A4 * |
TAKASU K ET AL: "Antileishmanial Activites of Rhodacyanine Dyes", HETROCYCLES, vol. 64, 2004, pages 215 - 221, XP002993399 * |
Also Published As
Publication number | Publication date |
---|---|
EP1800682B1 (en) | 2013-05-15 |
CN101031295B (zh) | 2012-01-25 |
CN101031295A (zh) | 2007-09-05 |
EP1800682A4 (en) | 2010-06-30 |
US20100113789A1 (en) | 2010-05-06 |
US8193224B2 (en) | 2012-06-05 |
JP2006104116A (ja) | 2006-04-20 |
JP4553355B2 (ja) | 2010-09-29 |
EP1800682A1 (en) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006038550A1 (ja) | 原虫寄生感染症の予防又は治療用医薬組成物 | |
Bhagdev et al. | Benzothiazole: As an antidiabetic agent | |
US8288374B2 (en) | Medicinal composition containing benzo[a]phenoxazine compound as the active ingredient for prevention or treatment of protozoal disease | |
WO2017035529A9 (en) | Compositions for app-selective bace inhibition and uses therfor | |
US8383656B2 (en) | Thiazolidinedione energy restriction-mimetic agents | |
WO2014124978A4 (en) | Helicase-primase inhibitors for use in a method of treating alzheimer's disease | |
JP4090133B2 (ja) | 抗マラリア剤 | |
US10968174B2 (en) | Synthesis of a thiosulfonic acid by a step of periodate mediated oxidative coupling of a thiosulfonic acid with an aniline | |
US20090036437A1 (en) | Pharmaceutical composition comprising phenoxazinium compound as an active ingredient | |
US7795285B2 (en) | Anti-trypanosomiasis agent | |
WO2001052849A1 (fr) | Remedes contre le diabete | |
US20090076067A1 (en) | Pharmaceutical composition comprising azarhodacyanine compound as active ingredient | |
JP4491229B2 (ja) | ミトコンドリアを保護するための医薬を調製するためのチアゾール誘導体の使用 | |
JP2021116291A (ja) | 2,4−ジアミノ−6,7−ジメトキシキナゾリン誘導体を有効成分として含有する医薬品組成物、及び特定の構造を有する2,4−ジアミノ−6,7−ジメトキシキナゾリン誘導体 | |
JP2003034640A (ja) | 四環性複素化合物を含有する抗マラリア剤 | |
WO2021193835A1 (ja) | 抗炎症型免疫強化剤 | |
KR20060017618A (ko) | 로르녹시캄 또는 로르녹시캄-유사체의 용도 | |
JP2024509265A (ja) | 赤血球増加症を処置するための組成物および方法 | |
EP4077320A1 (en) | Antiviral compounds, compositions and methods of use | |
JPWO2015056768A1 (ja) | 駆虫剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580033172.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2545/DELNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005787692 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11576429 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005787692 Country of ref document: EP |